Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $27.40.

Several analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, January 17th. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. BTIG Research dropped their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Finally, Guggenheim reissued a “buy” rating and issued a $12.00 price objective on shares of Outlook Therapeutics in a research note on Friday, January 17th.

Institutional Investors Weigh In On Outlook Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in shares of Outlook Therapeutics by 55.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock worth $275,000 after purchasing an additional 18,287 shares in the last quarter. State Street Corp increased its position in Outlook Therapeutics by 10.0% during the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after buying an additional 21,201 shares in the last quarter. Geode Capital Management LLC raised its stake in Outlook Therapeutics by 49.2% in the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock valued at $1,826,000 after buying an additional 112,812 shares during the last quarter. Barclays PLC boosted its holdings in Outlook Therapeutics by 677.4% in the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock worth $111,000 after acquiring an additional 18,249 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Outlook Therapeutics during the second quarter worth about $232,000. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Price Performance

Shares of OTLK stock opened at $1.73 on Friday. The company’s 50-day simple moving average is $1.88 and its two-hundred day simple moving average is $4.79. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85. The company has a market capitalization of $55.33 million, a P/E ratio of -0.19 and a beta of 0.58.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings data on Friday, December 27th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.06. On average, research analysts expect that Outlook Therapeutics will post -2.25 EPS for the current fiscal year.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.